## **ABCs Severe GAS Infection: Supplemental Form**

State ID:	S	ymptom onset date:/// _ <i>(mm/dd/yyyy)</i>		
	se enter clinical finding and/or labo IIGH or LOW values within 48 hours	☐ Unknown symptom onset date (check if unknown) oratory information requested below; or 2 days of culture or admission  ☐ Unknown symptom onset date (check if unknown) ☐ Form Approved ☐ O920-0978		
Soft-tissue necro	sis (necrotizina fasciitis, necrotizina m	nyositis, or necrotizing gangrene)? 1□Y 2□N 9□DK		
If yes, a. Location or b. Surgery? c. Amputation d. Debrideme	n body: 1 □Y 2 □N 9 □ DK n? 1 □Y 2 □N 9 □ DK			
2. Did the case have	any of the following sequelae from the	ne GAS infection? (Select all that apply)		
a.Dialysis? b.Impaired renal c.Rehabilitation? d.Other	I function? 1□Y 2□N 9□ ? 1□Y 2□N 9□	□DK If yes to 2c., please indicate rehab type: □DK 1□ Inpatient 2□ Outpatient 3□ Rehab facility □DK □DK (If yes to 2d., specify)		
3. Hypotension? 1⊟\	Y 2□N 9⊓DK Low	v systolic BP mmHg <i>or</i> □ not available		
(Systolic BP≤ 90mmHg; for children <10yrs, see Lab Values Table) (Enter abnormal or lowest hypotensive systolic BP found during this illness)				
***IF PATIENT DID NOT HAVE HYPOTENSION AT ANY TIME WITHIN 48 HOURS OR 2 DAYS OF CULTURE OR ADMISSION, PLEASE STOP HERE***				
4. a. Renal impairmen	nt? 1□Y 2□N 9□DK Highest crea	atinineng/dL <i>or</i>		
(Creatinine ≥2.12 mg/dL; for children <15yrs, see Lab  Values Table)  (If no chronic kidney disease, enter creatinine ≥2x upper limit of normal found during this illness.) If no abnormal value found or if chronic kidney disease, enter highest creatinine recorded during this illness.)				
b. Was chronic kidn	ney disease specifically listed in the ch	nart?1⊟Y 2⊟N		
Baseline or lowes	t creatinine:ng/dL <i>or</i> □ lab	value unavailable		
,	old or current charts) or lowest creatinine record	-		
<u>Date</u> of baseline v	ralue if obtained from current hospitali	<u>ization</u> :		
5 a. Coagulopathy? (Platelets ≤ 100,000/mr		(000)/mm³ or □lab value unavailable  ount ≤100,000/mm³ or lowest platelet count recorded during this illness.)		
b. Disseminated intra	avascular coagulation (DIC)? 1□Y	2□N 9□DK		
6a. Liver involvement?	1□Y 2□N 9□DK	b. Was chronic liver disease specifically listed 1 ☐ Y 2 ☐ N		
during this illness. If no abnormal Age ALT(SGPT)≥ or AST(	enter lab value that is ≥2x upper limit of normal found of value found or if <u>chronic</u> liver disease,enter highest (SGOT)≥ values recorded during this illness below.)	in the chart? (Enter baseline (from old or current charts) or lowest values recorded during this illness below. Enter dates of baseline values if obtained from current hospitalization.)		
F 80 U/L 1	200 U/L 190 U/L <u>Highest</u> 142 U/L	Baseline or lowest Date of baseline		
F 64 U/L 1	AST (SGOT) U/L	AST (SGOT) U/L / / (mm/dd/yyyy)		
	or □ lab value unavailable	or □ lab value unavailable		
	100 U/L 80 U/L ALT (SGPT) U/L	ALT (SGPT) U/L / / (mm/dd/yyyy)		
16 – 19 years: M 90 U/L	90 U/L or □ lab value unavailable	$or \; \square$ lab value unavailable		
	60 U/L Bilirubin mg/dL	Bilirubin mg/dL//		
Or Total bilirubin ≥ 2 mg/dL	or □lab value unavailable	or □ lab value unavailable ——,——,——— (''''''''''''		
<ul> <li>7. a. Acute respiratory distress syndrome (ARDS)?</li> <li>b. Acute onset of generalized edema?</li> <li>c. Pleural or peritoneal effusions with hypoalbuminemia?(Serum albumin &lt;3 g/dL or &lt; 30 g/L)</li> <li>Low albumin g/dL or □ lab value unavailable (Enter albumin &lt;3 g/dL or &lt; 30 g/L or lowest albumin recorded during this illness)</li> </ul>				
8. Generalized erythematous rash? 1□Y 2□N 9□DK				
Form completed by (initials): Date form completed:// (mm/dd/yyyy)				

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection information, including suggestions for reducing this burden to CDC, CDC/ATSDR Reports Clearance Officer, 1600 Clifton Road, MS D-74, Atlanta, GA 30329, ATTN: PRA(0920-0978). **Do not send the completed form to this address.** 

Age	Limit of normal range			
Systolic Blood Pressure				
0 – 28 days	<60 mm Hg			
1 month – 12 months	<70 mm Hg			
1 – 9 years	<70+(2x age in years)			
10 + years	<91 mm Hg			
Platelets				
All	≤100x10 <sup>9</sup> /L or ≤100,000/mm <sup>3</sup>			
Albumin				
All	<3g/dL or <30g/L			

All	<39/uL or <	<3g/aL or <30g/L		
Age	Normal range	Twice upper limit of normal range		
Creatinine <sup>1</sup>				
0 – 3 years	0.03 – 0.5 mg/dL	≥1 mg/dL		
4 – 9 years	0.03 – 0.59 mg/dL	≥1.18 mg/dL		
10 – 14 years	0.31 – 0.88 mg/dL	≥1.76 mg/dL		
15+ years	0.5 – 1.06 mg/dL	≥2.12 mg/dL		
Age	Normal range	Twice upper limit of normal range		
Alanine Aminotransferase <sup>1</sup> (ALT) or SGPT				
0 – 7 days	6 – 40 U/L	≥80 U/L		
8 – 30 days: Males Females	10 – 40 U/L 8 – 32 U/L	≥80 U/L ≥64 U/L		
1 – 12 months	12 – 45 U/L	≥90 U/L		
1 – 19 years	5 – 45 U/L	≥90 U/L		
20+ years	7 – 40 U/L	≥80 U/L		
	. 10 0/2			
Age	Normal range	Twice upper limit of normal range		
Age		normal range		
Age  Aspartate A  0 – 7 days: Male	Normal range minotransferase <sup>1</sup> (AST) 30 – 100 U/L	normal range or SGOT ≥200 U/L		
Age  Aspartate A  0 – 7 days: Male Female	Normal range minotransferase <sup>1</sup> (AST) 30 – 100 U/L 24 – 95 U/L	normal range or SGOT ≥200 U/L ≥190 U/L		
Age  Aspartate A  0 – 7 days: Male Female  8 – 30 days	Normal range minotransferase <sup>1</sup> (AST) 30 – 100 U/L 24 – 95 U/L 22 – 71 U/L	normal range or SGOT  ≥200 U/L ≥190 U/L ≥142 U/L		
Age  Aspartate A  0 – 7 days: Male Female  8 – 30 days  1 – 12 months	Normal range minotransferase¹ (AST) 30 – 100 U/L 24 – 95 U/L 22 – 71 U/L 22 – 63 U/L	normal range or SGOT  ≥200 U/L ≥190 U/L ≥142 U/L ≥126 U/L		
Age  Aspartate A  0 – 7 days: Male Female  8 – 30 days  1 – 12 months  1 – 3 years	Normal range minotransferase <sup>1</sup> (AST) 30 – 100 U/L 24 – 95 U/L 22 – 71 U/L 22 – 63 U/L 20 – 60 U/L	normal range or SGOT  ≥200 U/L ≥190 U/L ≥142 U/L ≥126 U/L ≥120 U/L		
Age  Aspartate A  0 – 7 days: Male Female  8 – 30 days  1 – 12 months	Normal range minotransferase¹ (AST) 30 – 100 U/L 24 – 95 U/L 22 – 71 U/L 22 – 63 U/L	normal range or SGOT  ≥200 U/L ≥190 U/L ≥142 U/L ≥126 U/L		
Age  Aspartate A  0 - 7 days: Male Female 8 - 30 days  1 - 12 months 1 - 3 years 4 - 9 years	Normal range minotransferase¹ (AST) 30 – 100 U/L 24 – 95 U/L 22 – 71 U/L 22 – 63 U/L 20 – 60 U/L 15 – 50 U/L	normal range or SGOT  ≥200 U/L ≥190 U/L ≥142 U/L ≥126 U/L ≥120 U/L ≥100 U/L		
Age  Aspartate A  0 - 7 days: Male Female  8 - 30 days  1 - 12 months  1 - 3 years  4 - 9 years  10-15 years  16-19 years: Male	Normal range minotransferase <sup>1</sup> (AST)  30 – 100 U/L  24 – 95 U/L  22 – 71 U/L  22 – 63 U/L  20 – 60 U/L  15 – 50 U/L  10 – 40 U/L  15 – 45 U/L	normal range or SGOT  ≥200 U/L ≥190 U/L ≥142 U/L ≥142 U/L ≥126 U/L ≥120 U/L ≥100 U/L ≥80 U/L ≥90 U/L		
Age  Aspartate A  0 - 7 days: Male Female 8 - 30 days  1 - 12 months 1 - 3 years 4 - 9 years 10-15 years 16-19 years: Male Female	Normal range minotransferase¹ (AST) 30 - 100 U/L 24 - 95 U/L 22 - 71 U/L 22 - 63 U/L 20 - 60 U/L 15 - 50 U/L 10 - 40 U/L 15 - 45 U/L 5 - 30 U/L	normal range or SGOT  ≥200 U/L ≥190 U/L ≥142 U/L ≥126 U/L ≥120 U/L ≥100 U/L ≥80 U/L ≥90 U/L ≥60 U/L		
Age  Aspartate A  0 - 7 days: Male Female 8 - 30 days  1 - 12 months  1 - 3 years  4 - 9 years  10-15 years  16-19 years: Male Female  20 + years  Age	Normal range minotransferase <sup>1</sup> (AST)  30 – 100 U/L 24 – 95 U/L 22 – 71 U/L 22 – 63 U/L 20 – 60 U/L 15 – 50 U/L 10 – 40 U/L 15 – 45 U/L 5 – 30 U/L 12 – 38 U/L	normal range or SGOT  ≥200 U/L ≥190 U/L ≥190 U/L ≥142 U/L ≥126 U/L ≥120 U/L ≥100 U/L ≥80 U/L ≥90 U/L ≥60 U/L ≥76 U/L  Twice upper limit of		

<sup>&</sup>lt;sup>1</sup> Kratz A, Pesce MA, Basner RC, Einstein AJ. Appendix: Laboratory Values of Clinical Importance. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine, 18e. New York, NY: The McGraw-Hill Companies; 2012. Local laboratories may have slightly different reference values.